María del Carmen
Chillón Santos
Investigadora desde 2011
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (10)
2023
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035
-
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155
2017
-
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106
2016
-
Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα
Leukemia, Vol. 30, Núm. 3, pp. 674-682
2014
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397
2008
2001
-
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group
British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103